Argent Biopharma (LSE:RGT) YoY EBITDA Growth : 5.84% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Argent Biopharma YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Argent Biopharma's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was 5.84%.

Argent Biopharma's EBITDA per Share for the six months ended in Dec. 2024 was £-0.13.

Argent Biopharma YoY EBITDA Growth Historical Data

The historical data trend for Argent Biopharma's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argent Biopharma YoY EBITDA Growth Chart

Argent Biopharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

YoY EBITDA Growth

Get a 7-Day Free Trial

-894.66

50.09

-2.48

2.45

93.87

Argent Biopharma Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
YoY EBITDA Growth	Get a 7-Day Free Trial															-40.17	14.19	94.01	91.82	5.84

Argent Biopharma YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Argent Biopharma's YoY EBITDA Growth for the fiscal year that ended in Jun. 2024 is calculated as:

	YoY EBITDA Growth (A: Jun. 2024 )
=	(EBITDA per Share (A: Jun. 2024 )	-	EBITDA per Share (A: Jun. 2023 ))	/	\| EBITDA per Share (A: Jun. 2023 ) \|
=	(-0.222	-	-3.623)	/	\| -3.623 \|
=	93.87 %

Argent Biopharma's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2024 )
=	(EBITDA per Share (Q: Dec. 2024 )	-	EBITDA per Share (Q: Dec. 2023 ))	/	\| EBITDA per Share (Q: Dec. 2023 )) \|
=	(-0.129	-	-0.137)	/	\| -0.137 \|
=	5.84 %

Argent Biopharma YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Argent Biopharma's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Argent Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (LSE:RGT) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

RGTLF:USA H5O0:Germany RGT:Australia

Address

295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008

Website

https://www.argentbiopharma.com

Argent Biopharma Ltd is a drug discovery company that addresses unmet medical needs. The company focuses on multidisciplinary methods with nanotechnology, developing multi-target therapies for comprehensive disease management, especially in the central nervous system and immunology treatments. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury, and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others.